SCHEDULE: N2OFF Insider Boosts Stake to 16.93%

Alon Silberman, CEO of N2OFF's subsidiary, has reported beneficial ownership of 16.93% of the company's common stock.

Summary

• Dr. Alon Silberman, CEO of MitoCareX Bio Ltd., a wholly-owned subsidiary of N2OFF, Inc., reported beneficial ownership of 454,127 shares of N2OFF Common Stock.
• This stake represents 16.93% of the company's outstanding Common Stock, calculated based on 2,682,483 shares issued and outstanding as of the filing date.
• The shares were acquired as part of a Securities Purchase and Exchange Agreement, as amended, dated February 25, 2025.
• The filing certifies that the securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant insider stake by a key executive, which is generally viewed as a positive signal of confidence in the company's prospects. However, it's a routine ownership disclosure, not a performance report.

Positives

• Significant insider ownership by a key executive (Dr. Alon Silberman, CEO of a wholly-owned subsidiary) demonstrates confidence in the company's future prospects.
• The acquisition of shares through a Securities Purchase and Exchange Agreement suggests a structured and potentially strategic investment by management.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategy.

Management Comments

• I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing is a routine disclosure of beneficial ownership and does not provide specific industry context or trends.

Related Party Transactions

• The acquisition of shares by Dr. Alon Silberman, CEO of a wholly-owned subsidiary, through a Securities Purchase and Exchange Agreement, constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the significant insider ownership as a positive indicator of management's confidence and alignment of interests.
• Management/Employees may see this as a reflection of commitment from a key executive to the company's long-term success.

Key Dates

Recommendation

The significant beneficial ownership reported by a key executive (16.93%) is a positive signal, indicating strong insider confidence and alignment of interests. However, a Schedule 13G filing primarily reports ownership and does not provide comprehensive financial or operational details to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and seek further financial disclosures and operational updates to make a more informed investment decision.

Keywords

N2OFF Inc., Alon Silberman, Beneficial Ownership, Schedule 13G, Common Stock, Insider Ownership, MitoCareX Bio Ltd., Equity Stake